Filtration of Macrophage Migration Inhibitory Factor (MIF) in Patients with End Stage Renal Disease Undergoing Hemodialysis

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2015 Oct 21

PMID 26485680

Citations 3

Authors

Peter Luedike

Christos Rammos

Julia Pohl

Martin Heisler

Matthias Totzeck

Werner Kleophas

Gerd R Hetzel

Malte Kelm

Ulrike Hendgen-Cotta

Tienush Rassaf

Affiliations

Soon will be listed here.

Abstract

Background: End stage renal disease (ESRD) patients are characterized by increased morbidity and mortality due to highest prevalence of cardiovascular disease. Macrophage migration inhibitory factor (MIF) is an inflammatory cytokine that controls cellular signaling in human physiology, pathophysiology, and diseases. Increased MIF plasma levels promote vascular inflammation and development of atherosclerosis. We have shown that MIF is associated with vascular dysfunction in ESRD patients. Whether hemodialysis (HD) affects circulating MIF plasma levels is unknown. We here aimed to investigate whether HD influences the circulating MIF pool in ESRD patients.

Methods And Results: An observational single-center study was conducted. MIF plasma levels in ESRD patients were assessed before, during, and after a HD session (n = 29). Healthy age-matched volunteers served as controls to compare correlations of MIF plasma levels with inflammatory plasma components (n = 20). MIF removed from the circulating blood pool could be detected in the dialysate and allowed for calculation of totally removed MIF (MIF content in dialysate 219±4 μg/HD-session). MIF plasma levels were markedly decreased 2 hour after initiation of HD (MIF plasma level pre-HD 84.8±6 ng/ml to intra-HD 61.2±5 ng/ml p<0.001) and were replenished already 20 min after termination of HD to basal levels (intra-HD 61.2±5 ng/ml to post-HD 79.8±5 ng/ml, p<0.001).

Conclusion: MIF is a dialyzable plasma component that is effectively filtrated during HD from the patient blood pool in large amounts. After removal of remarkable amounts of MIF during a single HD session, MIF plasma pool is early reconstituted after termination of HD from unknown sources.

Citing Articles

Predictive potential of macrophage migration inhibitory factor (MIF) in patients with heart failure with preserved ejection fraction (HFpEF).

Luedike P, Alatzides G, Papathanasiou M, Heisler M, Pohl J, Lehmann N Eur J Med Res. 2018; 23(1):22.

PMID: 29728137 PMC: 5935947. DOI: 10.1186/s40001-018-0321-1.

Myocardial Expression of Macrophage Migration Inhibitory Factor in Patients with Heart Failure.

Pohl J, Hendgen-Cotta U, Stock P, Luedike P, Baba H, Kamler M J Clin Med. 2017; 6(10).

PMID: 29027966 PMC: 5664010. DOI: 10.3390/jcm6100095.

Renal replacement therapy neutralizes elevated MIF levels in septic shock.

Pohl J, Papathanasiou M, Heisler M, Stock P, Kelm M, Hendgen-Cotta U J Intensive Care. 2016; 4:39.

PMID: 27313864 PMC: 4910205. DOI: 10.1186/s40560-016-0163-2.

References

Strussmann T, Tillmann S, Wirtz T, Bucala R, von Hundelshausen P, Bernhagen J . Platelets are a previously unrecognised source of MIF. Thromb Haemost. 2013; 110(5):1004-13. DOI: 10.1160/TH13-01-0049. View

Rammos C, Hendgen-Cotta U, Sobierajski J, Adamczyk S, Hetzel G, Kleophas W . Macrophage migration inhibitory factor is associated with vascular dysfunction in patients with end-stage renal disease. Int J Cardiol. 2013; 168(6):5249-56. DOI: 10.1016/j.ijcard.2013.08.021. View

Rassaf T, Weber C, Bernhagen J . Macrophage migration inhibitory factor in myocardial ischaemia/reperfusion injury. Cardiovasc Res. 2014; 102(2):321-8. DOI: 10.1093/cvr/cvu071. View

Rammos C, Hendgen-Cotta U, Pohl J, Totzeck M, Luedike P, Schulze V . Modulation of circulating macrophage migration inhibitory factor in the elderly. Biomed Res Int. 2014; 2014:582586. PMC: 4119621. DOI: 10.1155/2014/582586. View

Chatterjee M, Borst O, Walker B, Fotinos A, Vogel S, Seizer P . Macrophage migration inhibitory factor limits activation-induced apoptosis of platelets via CXCR7-dependent Akt signaling. Circ Res. 2014; 115(11):939-49. DOI: 10.1161/CIRCRESAHA.115.305171. View

Wirtz T, Tillmann S, Strussmann T, Kraemer S, Heemskerk J, Grottke O . Platelet-derived MIF: a novel platelet chemokine with distinct recruitment properties. Atherosclerosis. 2015; 239(1):1-10. DOI: 10.1016/j.atherosclerosis.2014.12.039. View

Miyazaki H, Matsuoka H, Itabe H, Usui M, Ueda S, Okuda S . Hemodialysis impairs endothelial function via oxidative stress: effects of vitamin E-coated dialyzer. Circulation. 2000; 101(9):1002-6. DOI: 10.1161/01.cir.101.9.1002. View

Mann J, Gerstein H, Pogue J, Bosch J, Yusuf S . Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med. 2001; 134(8):629-36. DOI: 10.7326/0003-4819-134-8-200104170-00007. View

Burger-Kentischer A, Goebel H, Seiler R, Fraedrich G, Schaefer H, Dimmeler S . Expression of macrophage migration inhibitory factor in different stages of human atherosclerosis. Circulation. 2002; 105(13):1561-6. DOI: 10.1161/01.cir.0000012942.49244.82. View

10.

Petrovsky N, Socha L, Silva D, Grossman A, Metz C, Bucala R . Macrophage migration inhibitory factor exhibits a pronounced circadian rhythm relevant to its role as a glucocorticoid counter-regulator. Immunol Cell Biol. 2003; 81(2):137-43. DOI: 10.1046/j.0818-9641.2002.01148.x. View

11.

Fassbinder W . Experience with the GENIUS hemodialysis system. Kidney Blood Press Res. 2003; 26(2):96-9. DOI: 10.1159/000070990. View

12.

Schober A, Bernhagen J, Thiele M, Zeiffer U, Knarren S, Roller M . Stabilization of atherosclerotic plaques by blockade of macrophage migration inhibitory factor after vascular injury in apolipoprotein E-deficient mice. Circulation. 2003; 109(3):380-5. DOI: 10.1161/01.CIR.0000109201.72441.09. View

13.

Anavekar N, McMurray J, Velazquez E, Solomon S, Kober L, Rouleau J . Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004; 351(13):1285-95. DOI: 10.1056/NEJMoa041365. View

14.

Go A, Chertow G, Fan D, McCulloch C, Hsu C . Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004; 351(13):1296-305. DOI: 10.1056/NEJMoa041031. View

15.

Bernhagen J, Calandra T, Bucala R . Regulation of the immune response by macrophage migration inhibitory factor: biological and structural features. J Mol Med (Berl). 1998; 76(3-4):151-61. DOI: 10.1007/s001090050204. View

16.

Stenvinkel P . Inflammation in end-stage renal disease: the hidden enemy. Nephrology (Carlton). 2006; 11(1):36-41. DOI: 10.1111/j.1440-1797.2006.00541.x. View

17.

Zernecke A, Bernhagen J, Weber C . Macrophage migration inhibitory factor in cardiovascular disease. Circulation. 2008; 117(12):1594-602. DOI: 10.1161/CIRCULATIONAHA.107.729125. View

18.

Rex S, Kraemer S, Grieb G, Emontzpohl C, Soppert J, Goetzenich A . The role of macrophage migration inhibitory factor in critical illness. Mini Rev Med Chem. 2015; 14(14):1116-24. DOI: 10.2174/1389557515666150203143736. View

19.

Bernhagen J, Krohn R, Lue H, Gregory J, Zernecke A, Koenen R . MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med. 2007; 13(5):587-96. DOI: 10.1038/nm1567. View

20.

Schober A, Bernhagen J, Weber C . Chemokine-like functions of MIF in atherosclerosis. J Mol Med (Berl). 2008; 86(7):761-70. DOI: 10.1007/s00109-008-0334-2. View